As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. The accrual ratio subtracts the FCF ...
Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and DocGo (DCGO – Research Report) with bullish sentiments.
Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...
Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...
Hosted on MSN6d
Cantor Fitzgerald Upgrades Sarepta Therapeutics (SRPT)Fintel reports that on November 7, 2024, Cantor Fitzgerald upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...
Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price ...
US drugmaker Sarepta Therapeutic saw its shares gain 2.4% to $127.97 as it reported financial results for the third quarter ...
Sarepta Therapeutics Inc (SRPT) reports a robust 39% revenue growth, achieving profitability while navigating strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback